Phase 2 winners

Five Phase 2 winners were each awarded $265,000 each for their refined solutions for detecting active Lyme disease infections in people.

BlueArc Biosciences Inc.

BlueArc Biosciences Inc.

Ultra-Sensitive Direct Diagnostic for Early Lyme Disease.

A molecular diagnostic blood test for Lyme B. burgdorferi s.l. using innovative polymerase chain reaction (PCR) assay that targets biomarkers for increased accuracy using standard laboratory equipment.

Drexel University College of Medicine

Drexel University College of Medicine

Glycoproteomic Approach to Lyme Disease Diagnostics.

A small-volume serum test using glycan biomarkers to detect active Lyme disease infection and track treatment response.

HelixBind Inc.

HelixBind Inc.

Ultra-Sensitive Direct Detection of Active Borrelia Infections.

An ultrasensitive, automated test to detect and identify active Lyme Borreliosis, direct from blood, in three hours.

T2 Biosystems Inc.

T2 Biosystems Inc.

T2Lyme Panel Direct Detection of Active Lyme Disease.

A whole blood test designed to directly detect Lyme disease-causing bacteria, providing results in three to five hours with higher accuracy.

Virginia Tech

Virginia Tech

Detecting The Release of Peptidoglycan for Direct Lyme Disease Diagnosis.

A test using monoclonal antibodies in conjunction with both immuno-PCR and lateral flow to rapidly detect a unique B. burgdorferi biomarker in blood and urine.

Phase 1 winners

The ten Phase 1 winners were recommended by the LymeX Diagnostics Prize judging panel. Each winner is awarded $100,000 and an exclusive invitation to participate in a planned Phase 2. In Phase 2, LymeX anticipates winners will prototype and refine their solutions with additional validation data and clinical protocol development.

BlueArc Biosciences Inc.

BlueArc Biosciences Inc.

Ultra-Sensitive Direct Diagnostic for Early Lyme Disease.

A molecular diagnostic blood test for Lyme B. burgdorferi s.l. using innovative polymerase chain reaction (PCR) assay that targets biomarkers for increased accuracy using standard laboratory equipment.

Drexel University College of Medicine

Drexel University College of Medicine

Glycoproteomic Approach to Lyme Disease Diagnostics.

A small-volume serum test using glycan biomarkers to detect active Lyme disease infection, track treatment response, and distinguish between diseases with similar symptoms.

George Mason University

George Mason University

Borrelia Derived, Sequence-Specific Novel Diagnostic Peptides.

A urine direct test that targets absolutely specific protein molecules and would provide direct information about pathogen activity.

HelixBind Inc.

HelixBind Inc.

Ultra-Sensitive Direct Detection of Active Borrelia Infections.

A test combining novel sample preparation and artificial nucleic acid detection to identify active infection in whole blood, synovial fluid, and cerebrospinal fluid.

InBios International Inc.

InBios International Inc.

Early Lyme Diagnosis Using a Microarray Immunoassay with Machine Learning.

An automated, quantified, array-based serum test using machine learning to improve sensitivity in categorizing specimens.

Massachusetts General Hospital

Massachusetts General Hospital

Cell-free Target Capture Sequencing for the Diagnosis of Lyme Disease.

A plasma test depleting human background material from samples and detecting low-abundance nucleic acid from tick-borne pathogens.

Serimmune Inc.

Serimmune Inc.

NGS-based Precision Serology for the Diagnosis of Tick-borne Disease.

A universal multiplex serum test that incorporates patient-centric surveillance testing, population data, and machine learning to enhance understanding of tick-borne diseases.

T2 Biosystems Inc.

T2 Biosystems Inc.

T2Lyme Panel Direct Detection of Active Lyme Disease.

A whole blood test designed to directly detect Lyme disease-causing bacteria, providing results in three to five hours with higher accuracy.

Tufts University

Tufts University

Antiphospholipid Antibodies for Tracking Lyme Disease After Treatment.

A serum test targeting a unique antibody that would more accurately identify early infection and allow clinicians to optimize additional treatment.

Virginia Tech

Virginia Tech

Detecting The Release of Peptidoglycan for Direct Lyme Disease Diagnosis.

A test using monoclonal antibodies in conjunction with immuno-PCR to detect a unique B. burgdorferi biomarker in multiple biofluids.